Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Video Recap - $ATE CEO Dan Legault & Radius Research

<< Previous

Bullboard Posts

Next >>

Post by bmreedon Nov 24, 2022 4:01pm

267 Views

Post# 35126188

Video Recap - $ATE CEO Dan Legault & Radius Research

Webinar Recap: Antibe Therapeutics $ATE w CEO Dan Legault - Pitch, Deep Dive and Q&A - https://youtu.be/5_M2ucaYGoQ

CEO Dan Legault provides a corporate update, including the progress of ATE's lead drug otenaproxesul, targeting acute pain, as well as updates on ATB-352 and its inflammatory bowel disease (IBD) program.